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Measles continues to be a major childhood disease in terms of global morbidity and mortality. In the main
areas of its endemicity the only available means of diagnosis are based on clinical criteria: the presence of a
maculopapular rash and fever accompanied by cough, coryza, and/or conjunctivitis. We have studied 38
clinically diagnosed cases of measles in Khartoum, Sudan, by means of serology, reverse transcriptase PCR
(RT-PCR) on throat swabs and virus isolation from lymphocytes. On the basis of serology, 28 patients were
diagnosed as having an acute measles virus (MV) infection, while in 10 cases the clinical symptoms proved to
have other causes. It was shown that in cases with low serum immunoglobulin M (IgM) levels, an additional
measurement of IgG or virus-neutralizing antibodies was necessary to discriminate between patients with an
acute MV infection sampled during an early stage of the disease and patients who had experienced an MV
infection in the more distant past. The serological laboratory diagnosis was validated by an MV-specific
RT-PCR: for all confirmed measles cases tested a fragment of the correct size which hybridized with a third
MV-specific primer could be amplified, while all serologically negative cases were also RT-PCR negative. MV
could be isolated from 17 out of 23 of the serologically confirmed cases, demonstrating that virus isolation is
less reliable as a diagnostic tool than serology or RT-PCR. This study stresses the urgent need for a rapid
diagnostic field test for measles.
Measles is a highly infectious respiratory virus infection, with
typical clinical symptoms including maculopapular rash, fever,
cough, coryza, and conjunctivitis. The causative agent of the
disease, measles virus (MV), is a negative-strand RNA virus of
the genus Morbillivirus, family Paramyxoviridae (11). Measles
continues to be a major cause of childhood morbidity and
mortality worldwide, with an estimated one million fatal cases
each year (2). Although the introduction of live attenuated MV
vaccines has largely abrogated the endemic circulation of wild-
type MV in the industrialized world, vaccination has been less
successful in large areas of Africa and Asia (4). This is thought
to be the combined result of insufficient vaccination coverage
due to limited infrastructure and/or political instability and
inherent disadvantages of the live attenuated vaccine such as
the need for cold chain maintenance and the interference by
maternal antibodies (5, 17).
Considering the World Health Organization (WHO) aim to
eradicate measles in the beginning of the next century, more
insight is required into the epidemiology and immunopatho-
genesis of measles in areas where the virus remains endemic.
During the course of an eradication campaign, the identifica-
tion of clinical cases becomes increasingly important. At
present, measles diagnosis in third-world countries is almost
exclusively based on the evaluation of clinical symptoms. How-
ever, due to the immunopathological nature of at least part of
the typical clinical symptoms of measles, not all patients in-
fected with MV present typical symptoms (11, 12). Further-
more, not every disease which fulfills the clinical criteria for
measles is necessarily caused by an infection with MV (8, 15).
The “gold standard” for laboratory diagnosis of an MV
infection is the demonstration of specific immunoglobulin M
(IgM) (10), either by a capture enzyme-linked immunosorbent
assay (ELISA) (7) or by immunofluorescence (6). A rapid,
cheap, and accurate test to detect MV-specific IgM antibodies
in a field setting is urgently needed but, at present, is not
available. Diagnostic measures based on demonstration of the
presence of the virus (either by reverse transcriptase PCR
[RT-PCR] or by virus isolation) are equally valid, but generally
less practicable in a routine setting. However, the widespread
application of lymphoblastoid cell lines instead of the tradi-
tional Vero cell cultures for the isolation of wild-type MV
strains (13) has greatly facilitated MV isolation procedures. As
a spin-off, sequence analysis of the increasing pool of MV
strains isolated in different parts of the world has proven to be
a powerful tool for molecular epidemiological studies, showing
the global distribution of different MV genotypes (1, 3). These
studies will be of crucial importance during the final stages of
the MV eradication program.
Here, we present the serological and virological character-
ization of a group of 38 clinical measles cases collected in
Khartoum, Sudan, by demonstration of MV-protein-specific
serum IgM, IgG, and virus-neutralizing (VN) antibody levels,
RT-PCR signals in throat swabs, and MV isolation from pe-
ripheral blood mononuclear cells (PBMC).
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MATERIALS AND METHODS
Patients. Clinical materials were collected from infants who met the WHO
clinical case definition for measles: “any person with a generalized maculopap-
ular rash (i.e., nonvesicular), and a history of fever of 38°C or more, and at least
one of the following: cough, coryza (i.e., runny nose), or conjunctivitis (i.e., red
eyes); or: any person in whom a health professional suspects measles” (9). The
clinical symptoms were always present at the moment of sampling. Samples were
collected after having obtained informed consent from the parents. The collec-
tion of clinical specimens was an integral part of an ongoing prospective measles
study in Khartoum (started in April 1997), which was approved by the medical
ethical committee of the University of Khartoum. The samples collected during
the first 6 months of the integral study period are presented here.
Study area. Most of the patients (n 5 30) were sampled through a network
which was set up in the residential area Haj Yousif for finding cases of measles.
This area of Khartoum has an estimated 500,000 inhabitants, mainly comprised
of displaced people from the south and west of Sudan. Health care in the area
is provided through volunteer health centers, often by staff members with limited
clinical backgrounds. Measles vaccination coverage is low, and endemic MV
transmission occurs throughout the year. The cases included in this study did not
present as an outbreak, but were spread over the 6-month period. The number
of cases observed during this period was not substantially different from that
observed in any other period of the year or from any other year between 1995
and the present. The number of reported patients that could not be sampled was
less than half of the number of patients included in the study. Eight additional
patients were sampled in pediatric hospitals in Khartoum.
Samples. Clinical specimens collected consisted of a throat swab and a hep-
arinized blood sample (approximately 3 ml). PBMC were isolated by density
gradient centrifugation in Khartoum and were frozen in RPMI medium supple-
mented with 40% fetal bovine serum (FBS) and 10% dimethyl sulfoxide in liquid
nitrogen. Plasma and throat swabs were frozen at 270°C.
Serology. Plasma levels of IgM or IgG specific for the two MV transmembrane
glycoproteins, the fusion protein (F) and hemagglutinin (H), were determined by
an immunofluorescence assay by using transfected human melanoma cell lines as
targets, as previously described (6). Briefly, melanoma cells expressing either the
F protein (Mel-JuSo/MV-F) or the H protein (Mel-JuSo/MV-H) or the untrans-
fected parental cell line (Mel-JuSo/wt) were incubated with diluted plasma sam-
ples. The samples were prediluted 1:10 in phosphate-buffered saline supple-
mented with 2% FBS (for measurement of MV-specific IgG) or in GullSorb
reagent (Gull Laboratories, Salt Lake City, Utah) to precipitate all plasma IgG
for measurement of MV-specific IgM. Subsequently, the samples were diluted
1:10 in phosphate-buffered saline supplemented with 2% FBS to reach a final
dilution of 1:100. After 1 h on ice, the cells were washed and stained with
fluorescein isothiocyanate-labeled rabbit anti-human IgM or IgG [F(ab9)2 frag-
ments; DAKO, Glostrup, Denmark]. Results are expressed as the fluorescence
signal (histogram peak channel) measured on a FACScan (Becton-Dickinson,
Mountainview, Calif.) in arbitrary fluorescence units (AFU). Fluorescence sig-
nals measured on the untransfected cell line were always below 10 AFU (data not
shown).
Plasma levels of IgM specific to the nucleoprotein (N) were measured in a
capture ELISA by using peroxidase-labeled purified baculovirus-expressed N
(N-PO). Plasma samples were diluted 1:100 in ELISA buffer (Meddens Diag-
nostics, Brummen, The Netherlands) and were incubated on ELISA plates
(Greiner, Alphen a/d Rijn, The Netherlands) coated with rabbit anti-human IgM
(Meddens Diagnostics). After 1 h at 37°C, plates were washed in water contain-
ing 0.05% Tween-80 and were subsequently incubated with N-PO. Following an
additional 1 h incubation at 37°C, the plates were washed again and were
subsequently colored using tetramethylbenzidine as a substrate. Extinctions were
read in an ELISA reader at 450 nm.
Plasma levels of VN antibodies were measured as previously described (14)
with minor modifications. Briefly, serial twofold dilutions of the plasma samples
were tested for their ability to neutralize 60 50% tissue culture infective doses of
the MV Edmonston strain. Plasma dilutions were prepared in Dulbecco’s mod-
ified Eagle medium (BioWhittaker, Verviers, Belgium) supplemented with 2%
FBS, of which 50 ml was incubated with 50 ml of the virus working dilution in
96-well flat bottom plates (Greiner). After 1 h at 37°C (neutralization phase),
Vero cells were added (104 cells in 50 ml per well). Cells were microscopically
monitored for cytopathic effects (CPE) during the following week. For each
plasma sample, eight dilutions (1:32 to 1:4,096, dilution during neutralization
phase) were tested in triplicate. The results are shown as the dilution at which
50% of the cultures was neutralized, calculated as previously described (18),
standardized to the WHO international standard (0.2 IU/ml), which was found to
have a 50% VN titer of 54.
Virus isolation. MV was isolated from PBMC by an infectious center assay as
previously described (20). PBMC (3.2 3 105) were divided over 8 wells of a
96-well round-bottom plate (Greiner) and stimulated with phytohemagglutinin
(Boehringer GmbH, Mannheim, Germany) for 1 h at 37°C, after which twofold
serial dilutions were prepared in RPMI medium supplemented with 10% FBS
(each dilution range was prepared eight times). Subsequently, a standard amount
(5 3 103 per well) of a human Epstein-Barr virus-transformed B-lymphoblastic
cell line previously established from a healthy volunteer (GR) was added to each
well. In the case of positive virus isolations, CPE were usually observed 2 to 4
days after culture at 37°C. The level of viremia (i.e., the number of MV-infected
cells per 106 PBMC) was determined by calculating the number of PBMC per
well resulting in 50% of the cultures showing CPE (18) and is presented as the
number of MV-infected cells per 106 PBMC.
In the case of a positive MV isolation, as determined by the observation of
typical MV-related CPE, the supernatant of one to three wells showing CPE at
the upper range of the serial dilutions was harvested and cocultivated with
approximately 5 3 106 cells of B-lymphoblastic cell line GR in a 25-cm2-volume
culture flask. When these cells showed CPE 2 to 3 days later, cell-free superna-
tant was harvested and aliquots were frozen at 270°C.
RT-PCR. The presence of MV genomic RNA in throat swab samples was
determined by RT-PCR by using a forward primer in the N gene and a reverse
primer in the region between the N gene and the P-C-V gene. Briefly, RNA was
isolated from 200-ml of throat swab material by using the High Pure Viral RNA
kit (Roche Diagnostics, Almere, The Netherlands) and was analyzed by RT-PCR
by using random hexanucleotides for first-strand synthesis. Primers used for
amplification were as follows: forward 59-TTAGGGCAAGAGATGGTAAG
G-39 (MV-N1, position 1090-1110) (19) and reverse, 59-TTATAACAATGATG
GAGGG-39 (MV-N2, position 1615-1633). PCR products were separated on a
2% agarose gel and blotted onto Hybond N1 membrane (Amersham Pharmacia
Biotech, Uppsala, Sweden). Hybridization was performed by using a 32P-labeled
oligo probe (59-GCCATGGCAGGAATCTCGGAA-39 [MV-prN2, position
1498-1518]).
RESULTS
Laboratory diagnosis by serology. Blood samples were col-
lected from 38 clinically diagnosed measles patients (age
range, 5 months to 14 years) within six days after onset of the
rash (Table 1). Immunofluorescence with MV-F and MV-H
transfected cell lines demonstrated the absence of MV glyco-
protein-specific IgM in the plasma of 10 of these patients (Fig.
1A). In one patient, SM32, the result of the assay was indeter-
minate based on previously established cutoffs (signal, ,30
AFU), while the other 27 patients all demonstrated the pres-
ence of both MV-F- and MV-H-specific plasma IgM (Fig. 1A).
The MV-F- and MV-H-specific immunofluorescence signals
showed a good correlation (linear regression analysis, r2 5
0.82). We subsequently compared the mean MV glycoprotein-
specific IgM response with the MV N-specific IgM response
(Fig. 1B). Of the 10 patients who were IgM negative in the
glycoprotein-specific assays, one patient (SM17) gave a low
positive result in the N-specific-IgM capture ELISA, while the
other nine were negative in this assay. The 27 patients who
were glycoprotein-specific-IgM positive and the indeterminate
patient (SM32) were also N-specific-IgM positive, although
SM32 showed an N-specific signal which was intermediate be-
tween SM17 and the 27 high positives.
On the basis of these MV IgM assays, 36 out of 38 cases
could be diagnosed as being either acute MV infections (n 5
27) or nonmeasles rash diseases (n 5 9). In order to serolog-
ically diagnose the two low-positive IgM patients, additional
IgG and VN assays were carried out. As shown in Fig. 1C,
SM17 had high serum levels of glycoprotein-specific IgG and
VN antibodies while SM32 was glycoprotein-specific IgG and
VN negative, suggesting that the first was a nonmeasles rash
disease patient while the second was sampled at an early stage
of an MV infection. Of the other nine MV-IgM-negative cases,
two (SM9 and SM19) contained high levels of MV-specific
IgG, three contained low levels of MV-specific IgG, and four
were completely IgG negative (Fig. 1C).
Laboratory diagnosis by RT-PCR and virus isolation. In
addition to serology, MV-specific RT-PCR on throat swab
material and MV isolation from PBMC were carried out with
the clinical specimens available. As shown in Table 1, 20 out of
20 serologically confirmed MV cases tested (including SM32)
were RT-PCR positive, while all 10 serologically confirmed
MV-negative cases (including SM17) were RT-PCR negative.
MV could be isolated from PBMC of 17 out of 23 serologically
confirmed MV cases (including SM32) but from none of six
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serologically confirmed MV-negative cases (including SM17,
see Table 1). Levels of infected cells were as high as about
10,000 infected cells per 106 PBMC (see Table 1), with the
highest level in patient SM32. MV isolation from swab mate-
rial was far less successful than from PBMC: MV could be
isolated from only three of the 20 serologically confirmed cases
tested.
DISCUSSION
In the present paper, we have serologically and virologically
analyzed 38 clinically diagnosed measles cases in Khartoum,
Sudan. Measurement of MV-specific IgM, IgG, and VN anti-
bodies, as well as RT-PCR on throat swab samples and MV
isolation from PBMC, demonstrated that in 28 of the 38 cases
(74%) the disease was indeed caused by an acute MV infec-
tion, but in 10 patients (26%) the disease had another cause.
Misdiagnosis of measles on clinical grounds has often been
reported (8, 15, 16). The diagnosis of measles can be difficult,
even for experienced practitioners, especially in individuals
with a pigmented skin. A number of different infectious agents,
including Parvovirus B19, human herpesvirus type 6, Dengue
virus, Epstein-Barr virus, Mycoplasma pneumoniae, and Rick-
ettsia conorii, are known to cause symptoms that can easily be
confused with measles and are also known to be endemic in
this part of Africa (15). In the framework of the envisaged MV
eradication program, rapid and reliable assays to diagnose
these infections will be crucial.
Measurement of MV-specific IgM antibodies proved to be
sufficient to diagnose 36 of the 38 clinically diagnosed measles
cases. We measured the IgM antibody response to the three
major immunogenic MV proteins: the transmembrane glyco-
proteins F and H and the internal protein N. For routine
diagnostic purposes, a capture ELISA such as the one pre-
sented here based on peroxidase-labeled N would be the first
choice. In case of low positive specific IgM signals, there are
TABLE 1. Summary of patient baseline data and results of laboratory assays
Case
designationa Gender
b Age (mo) Rash(days after onset)
IgMc
(plasma)
RT-PCRd
(throat)
MV isolation
(PBMC)
No. of infected cells
(per 106 PBMC)e
SM4 F 16 1 1 NDf 2 ,3
SM5 M 12 1 1 1 ND ND
SM8 F 42 3 1 1 ND ND
SM11 M 8 2 1 ND 1 6
SM14 F 24 2 1 ND 2 ,3
SM16 M 18 2 1 ND 2 ,3
SM23 F 48 5 1 1 1 6
SM24 F 14 5 1 1 1 10
SM25 F 48 3 1 1 1 925
SM26 F 20 3 1 1 1 50
SM27 M 23 3 1 1 1 3
SM28 F 15 2 1 1 1 350
SM29 M 168 4 1 ND 1 150
SM30 M 48 3 1 1 ND ND
SM31 F 120 4 1 1 1 3
SM32 M 14 2 1/2 1 1 9,700
SM33 F 96 2 1 1 ND ND
SM34 M 132 4 1 1 1 80
SM37 M 7 4 1 1 1 925
SM38 M 11 4 1 ND 2 ,3
SM39 M 10 6 1 1 2 ,3
SM40 F 24 2 1 1 1 200
SM41 M 36 2 1 1 ND ND
SM42 F 12 4 1 1 1 525
SM43 F 5 3 1 1 2 ,3
SM44 F 8 3 1 ND 1 100
SM45 F 10 3 1 ND 1 300
SM46 F 23 3 1 1 1 3
SM1 F 48 3 2 2 ND ND
SM2 F 48 2 2 2 ND ND
SM3 M 54 3 2 2 ND ND
SM9 M 15 1 2 2 2 ,3
SM17 M 42 3 1/2 2 2 ,3
SM18 M 18 4 2 2 2 ,3
SM19 M 36 2 2 2 2 ,3
SM20 M 11 3 2 2 2 ,3
SM21 M 20 4 2 2 2 ,3
SM22 M 33 4 2 2 ND ND
a Laboratory-confirmed MV cases (see results section) are listed in the upper part of the table, and serologically confirmed MV-negative cases are listed in the lower
part.
b F, female; M, male.
c As shown in Fig. 1.
d Positive if fragment of correct length which hybridized with the specific probe was amplified.
e Determined by infectious center test as described in Materials and Methods.
f ND, not done.
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three theoretical possibilities: the patient is in an early stage of
an MV infection (with a nascent IgM response), the patient
had an MV infection some months ago and is now suffering
from a nonmeasles rash disease, or the patient was previously
vaccinated and is undergoing a secondary immune response
associated with a transient low-level IgM response. The latter
category should be discriminated from the first two on the basis
of the clinical signs: if the patient has a normal measles rash
accompanied with conjunctivitis, the patient is most probably
undergoing a primary immune response. Since this was the
case for SM17 and SM32, we tried to discriminate between the
first two possibilities by measuring MV-specific IgG and VN
antibody levels. During the early phase of an MV-specific im-
mune response, specific IgM antibodies appear before or at the
same time as specific IgG antibodies. When the levels of IgM
antibodies start to decrease a few weeks later, the levels of
specific IgG and VN antibodies have reached a plateau value
(6, 11). SM17 could be identified as a case of nonmeasles rash
disease, since the low MV-specific IgM antibody levels were
accompanied by high IgG and VN antibody levels. In contrast,
SM32 proved to be a laboratory-confirmed MV infection, since
the low levels of MV-specific IgM antibodies were accompa-
nied by undetectable IgG and VN levels. This serological di-
agnosis was confirmed by RT-PCR and MV isolation: SM17
was negative while SM32 was positive in both assays. Further-
more, assessment of the level of viremia further confirmed that
patient SM32 was in an early stage of infection, as this patient
had the highest level of infected cells.
To our knowledge, the use of an RT-PCR for the diagnosis
of normal measles cases has not been described previously. In
our study, an RT-PCR using throat swab materials proved to
completely correlate with the serological diagnosis of MV. The
RT-PCR described may be used in serologically doubtful cases.
However, it will especially be of value in cases of suspected MV
infections in immunocompromised individuals in which clinical
and serological diagnosis is often impossible. MV isolation
from PBMC proved less reliable as a diagnostic tool, since MV
could not be isolated from six out of 23 (26%) serologically
confirmed MV cases. We hypothesize that in most of these
cases this was due to practical problems related to suboptimal
sampling, handling, and/or freeze-thawing procedures. Isola-
tion and storage of PBMC in an African setting is often difficult
to organize, as the required freezing facilities (2135°C or
lower) are rarely available. The success rate of virus isolation
from PBMC was significantly higher than the success rate of
virus isolation from swab material: in 85% of the serologically
confirmed MV cases no MV could be isolated from swabs. This
included some of the cases in which the presence of MV
genomic RNA was demonstrated by RT-PCR. Apparently, the
capacity of viable PBMC to produce new virus particles, espe-
cially following phytohemagglutinin stimulation, strongly fa-
vors this method of MV isolation. An alternative and generally
easy to obtain clinical source for the isolation of MV would be
urine. However, this was not evaluated in the present study.
In conclusion, our study has shown that a substantial per-
centage (26%) of the measles cases identified on the basis of
the symptoms specified in the WHO clinical case definition (9)
were misdiagnosed. Serological methods were sufficient for a
laboratory diagnosis of MV infection: measurement of MV-
specific IgM alone could diagnose 95% of the patients, while
the remainder could be diagnosed with an additional IgG or
VN assay. RT-PCR on throat swab material proved to be an
equally valid diagnostic assay, which is, however, less practica-
ble in a routine setting. In combination with virus isolation it
does, however, provide the tools for phylogenetic analyses,
allowing molecular epidemiological studies which will be of
crucial importance in the end stages of the envisaged MV
eradication program.
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